Industry News
BRC branches into MS
The Brain Resource Company (ASX:BRC) is to supply its services to a Schering Israel funded Multiple Sclerosis study. [ + ]
Biotech stocks fall in January
Biotechnology stocks have continued to underperform in January -- with the Intersuisse biotechnology index sliding by 0.9 per cent. [ + ]
CSL to enter US flu market, double vaccine capacity
Biopharmaceutical company CSL (ASX:CSL) will invest AUD$80 million in plant and equipment to double capacity at its Melbourne facility to 40 million doses per season, making it one of the largest vaccine manufacturing plants in the world. [ + ]
UQ team to test therapeutic HPV vaccine
A research team at the University of Queensland, headed by Prof Ian Frazer, is said to have developed a new, therapeutic vaccine for genital warts, and is about to begin phase II trials in Australia and China. [ + ]
Liver diagnostic technology
Resonance Health's non-invasive liver diagnostic technology uses magnetic resonance imaging (MRI) technology to provide a scan of the liver which is subsequently analysed to quantify iron loading using FerriScan's proprietary software. It is a novel technology easily applied to anyone with an MRI machine.
[ + ]Eqitx CEO says 'no cash flow issues'
Melbourne-based Eqitx (ASX:EQX) was asked by the ASX last week to explain its financial position following the announcement it had invested a further $500,000 to increase its equity in vaccine developer VacTX. [ + ]
Prana completes Alzheimer's phase I
Melbourne's Prana Biotechnology (ASX:PBT, Nasdaq:PRAN) has successfully completed a second phase I trial of its lead compound PBT2, under development as a therapy for Alzheimer's disease. [ + ]
Over the counter, into the black
Singapore-based, ASX-listed Rockeby Biomed (ASX:RBY) has changed its focus and managing director Dr Sze Wee Tan has a positive outlook for this year. Helen Schuller reports. [ + ]
Why Chance takes no chances on GM
Western Australia's agriculture minister, Kim Chance, is taking what many are now seeing as an overly cautious stance on biotechnology. Graeme O'Neill reports. [ + ]
Industry groups warn PBS changes dangerous for biotech
Widely-touted changes to Australia's Pharmaceutical Benefits Scheme (PBS) could cost the biotech industry more than AUD$300 million in investment annually, according to AusBiotech. [ + ]
Local councils to join Victorian biotech industry
A new study identifying ways that local government can assist the biotech industry was launched by Victorian minister for innovation John Brumby yesterday. [ + ]
Tracking performance in real time
Traqua, developed by the CRC for microTechnology for the Australian Institute of Sport (AIS), is the leading edge of the next sports revolution - providing hard data in real time on an athlete's motion to reinforce the coach's eye and instincts.
[ + ]How viruses enter cells
A team of Northwestern University researchers has solved the structure of a molecule that controls the ability of viruses of the paramyxovirus family, including the viruses that cause measles, mumps, and many human respiratory diseases, to fuse with and infect human cells.
[ + ]In brief: Genesis Biomedical, Select Vaccines, Pharmaxis
Sydney-based Genesis Biomedical (ASX:GBL) has closed its underwritten share offer early and oversubscribed raising AUD$2.4 million, substantially boosting its coffers -- the firm had $586,000 at the end of the quarter. [ + ]
Mesoblast implants two with adult stem cells
The first two patients in Melbourne-based Mesoblast's (ASX:MSB) clinical trials have been implanted with adult stem cells. [ + ]
